indapamide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diuretics, sulfamoylbenzoic acid derivatives 1433 26807-65-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metindamide
  • indapamide hemihydrate
  • indapamide
  • flupamid
  • indaflex
  • indamide
  • indamol
  • veroxil
  • (+/-)-Indapamide
A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
  • Molecular weight: 365.83
  • Formula: C16H16ClN3O3S
  • CLOGP: 2.96
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 92.50
  • ALOGS: -4.03
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.59 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.20 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
July 6, 1983 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 1389.88 12.54 775 22921 100557 46561809
Hypokalaemia 546.36 12.54 410 23286 87614 46574752
Acute kidney injury 316.11 12.54 485 23211 235370 46426996
Confusional state 146.27 12.54 278 23418 159614 46502752
Inappropriate antidiuretic hormone secretion 127.68 12.54 83 23613 14019 46648347
Drug interaction 123.31 12.54 299 23397 202795 46459571
Hyponatraemic seizure 109.45 12.54 29 23667 458 46661908
Hypochloraemia 99.45 12.54 37 23659 1836 46660530
Burning mouth syndrome 80.86 12.54 22 23674 386 46661980
Lactic acidosis 77.87 12.54 91 23605 33818 46628548
Conjoined twins 69.23 12.54 18 23678 263 46662103
Allergic reaction to excipient 66.97 12.54 18 23678 301 46662065
Torsade de pointes 65.06 12.54 52 23644 12102 46650264
Completed suicide 61.55 12.54 3 23693 145917 46516449
Death 60.58 12.54 49 23647 335499 46326867
Labile hypertension 58.69 12.54 18 23678 490 46661876
Hypomagnesaemia 58.47 12.54 64 23632 22146 46640220
Intestinal malrotation 51.77 12.54 15 23681 334 46662032
Drug ineffective 51.36 12.54 175 23521 677663 45984703
Congenital bladder anomaly 50.78 12.54 13 23683 178 46662188
Urachal abnormality 50.51 12.54 13 23683 182 46662184
Angioedema 49.69 12.54 79 23617 39263 46623103
Persistent cloaca 49.38 12.54 13 23683 200 46662166
Fall 46.69 12.54 306 23390 328791 46333575
Electrocardiogram QT prolonged 46.48 12.54 89 23607 51236 46611130
Psychomotor retardation 44.74 12.54 25 23671 3208 46659158
Sprue-like enteropathy 44.07 12.54 14 23682 429 46661937
Product packaging confusion 43.71 12.54 11 23685 140 46662226
Hypotension 42.39 12.54 231 23465 232358 46430008
Rhabdomyolysis 42.11 12.54 76 23620 41833 46620533
Exposure during pregnancy 35.69 12.54 6 23690 108206 46554160
Metabolic acidosis 34.80 12.54 67 23629 38713 46623653
Orthostatic hypotension 34.61 12.54 52 23644 24606 46637760
Bradycardia 34.25 12.54 92 23604 66206 46596160
Renin increased 33.18 12.54 9 23687 156 46662210
Maternal exposure during pregnancy 33.13 12.54 6 23690 102543 46559823
Hypertensive angiopathy 32.78 12.54 8 23688 89 46662277
Eye oedema 31.51 12.54 15 23681 1380 46660986
Product dose omission issue 31.11 12.54 24 23672 168496 46493870
Left ventricular hypertrophy 30.40 12.54 23 23673 4940 46657426
Hyperlactacidaemia 30.30 12.54 17 23679 2198 46660168
Renal impairment 28.67 12.54 93 23603 74279 46588087
Limb malformation 27.79 12.54 10 23686 451 46661915
Ischaemic stroke 27.47 12.54 38 23658 16684 46645682
Rheumatoid arthritis 27.47 12.54 50 23646 240165 46422201
Vessel puncture site haemorrhage 27.20 12.54 7 23689 98 46662268
Atrial fibrillation 26.88 12.54 114 23582 103476 46558890
Blood pressure increased 26.63 12.54 131 23565 126535 46535831
Syncope 26.17 12.54 114 23582 104689 46557677
Dyslipidaemia 26.08 12.54 22 23674 5518 46656848
Dehydration 25.44 12.54 153 23543 159387 46502979
Labelled drug-drug interaction medication error 25.40 12.54 27 23669 9034 46653332
Vomiting 25.26 12.54 345 23351 452449 46209917
Hypoglycaemia 24.70 12.54 72 23624 54277 46608089
Hypouricaemia 24.07 12.54 7 23689 158 46662208
Urine albumin/creatinine ratio increased 23.82 12.54 7 23689 164 46662202
Disorientation 22.99 12.54 55 23641 36863 46625503
Drug hypersensitivity 22.66 12.54 57 23639 243768 46418598
Blood sodium decreased 22.59 12.54 40 23656 21686 46640680
Off label use 22.36 12.54 108 23588 379733 46282633
Paramnesia 21.96 12.54 4 23692 8 46662358
Blood pressure inadequately controlled 21.78 12.54 18 23678 4388 46657978
Infection 21.09 12.54 22 23674 133570 46528796
Eosinophilia 20.78 12.54 36 23660 19181 46643185
Diabetic hyperosmolar coma 20.68 12.54 8 23688 442 46661924
Mucocutaneous haemorrhage 20.54 12.54 5 23691 55 46662311
Postictal state 20.40 12.54 10 23686 981 46661385
Anuria 20.33 12.54 27 23669 11404 46650962
Blood electrolytes abnormal 20.33 12.54 10 23686 989 46661377
Fatigue 19.68 12.54 206 23490 608491 46053875
Blood osmolarity decreased 19.65 12.54 9 23687 759 46661607
Hypertension 19.49 12.54 168 23528 196188 46466178
Cerebral haematoma 19.41 12.54 15 23681 3324 46659042
Haematoma 19.33 12.54 47 23649 31825 46630541
Hypovolaemic shock 19.25 12.54 18 23678 5165 46657201
Pain 19.05 12.54 153 23543 476795 46185571
Eosinophilic pneumonia 18.97 12.54 12 23684 1932 46660434
Vulvovaginal inflammation 18.82 12.54 8 23688 564 46661802
Hyponatraemic syndrome 18.56 12.54 8 23688 584 46661782
Proctalgia 18.48 12.54 17 23679 4779 46657587
Stevens-Johnson syndrome 18.20 12.54 38 23658 23259 46639107
Ear haemorrhage 18.08 12.54 10 23686 1258 46661108
Iron deficiency 18.04 12.54 18 23678 5595 46656771
Platelet dysfunction 18.00 12.54 5 23691 95 46662271
Circulatory collapse 17.75 12.54 36 23660 21588 46640778
Deprescribing error 17.69 12.54 4 23692 31 46662335
Injection site pain 17.65 12.54 17 23679 107135 46555231
Blood pressure abnormal 17.48 12.54 26 23670 12191 46650175
Serratia infection 17.02 12.54 8 23688 715 46661651
Systemic lupus erythematosus 16.86 12.54 6 23690 65174 46597192
Peripheral artery haematoma 16.78 12.54 4 23692 40 46662326
Alopecia 16.66 12.54 36 23660 162378 46499988
Proteinuria 16.60 12.54 30 23666 16523 46645843
Gravitational oedema 16.58 12.54 9 23687 1091 46661275
Bradyphrenia 16.47 12.54 18 23678 6212 46656154
Normocytic anaemia 16.29 12.54 9 23687 1130 46661236
Treatment failure 16.24 12.54 14 23682 93073 46569293
Rectal polyp 16.04 12.54 8 23688 815 46661551
Myalgia 15.91 12.54 112 23584 122976 46539390
Injection site erythema 15.88 12.54 9 23687 74418 46587948
Inclusion body myositis 15.87 12.54 3 23693 8 46662358
Face oedema 15.86 12.54 32 23664 19121 46643245
Electrolyte imbalance 15.74 12.54 30 23666 17196 46645170
Vertigo 15.66 12.54 60 23636 51988 46610378
Depression 15.61 12.54 40 23656 170064 46492302
Metabolic alkalosis 15.57 12.54 12 23684 2648 46659718
Hypotonia 15.51 12.54 20 23676 8209 46654157
Protrusion tongue 15.50 12.54 6 23690 332 46662034
Glomerular filtration rate decreased 15.47 12.54 24 23672 11670 46650696
Impaired work ability 15.43 12.54 25 23671 12611 46649755
Glycosylated haemoglobin increased 15.35 12.54 23 23673 10853 46651513
General physical health deterioration 15.35 12.54 106 23590 115663 46546703
Hypocalciuria 15.14 12.54 3 23693 11 46662355
Intracranial haematoma 15.08 12.54 6 23690 357 46662009
Tongue oedema 15.05 12.54 14 23682 3992 46658374
Leukocyturia 14.97 12.54 8 23688 940 46661426
Convulsive threshold lowered 14.94 12.54 6 23690 366 46662000
Rash maculo-papular 14.71 12.54 39 23657 27835 46634531
Pyelonephritis acute 14.67 12.54 14 23682 4120 46658246
Haemorrhagic stroke 14.57 12.54 16 23680 5550 46656816
Intestinal transit time abnormal 14.55 12.54 4 23692 73 46662293
Oliguria 14.53 12.54 20 23676 8739 46653627
Drug abuse 14.52 12.54 7 23689 63401 46598965
Hospitalisation 14.51 12.54 7 23689 63378 46598988
Disease progression 14.44 12.54 15 23681 91285 46571081
Hypernatriuria 14.39 12.54 3 23693 15 46662351
Sensitisation 14.25 12.54 7 23689 690 46661676
Gastroenteritis salmonella 13.89 12.54 6 23690 440 46661926
Thrombophlebitis 13.84 12.54 14 23682 4423 46657943
Urine output decreased 13.61 12.54 22 23674 11075 46651291
Infusion related reaction 13.49 12.54 19 23677 101189 46561177
Lymphocytic infiltration 13.29 12.54 7 23689 799 46661567
Cognitive disorder 13.20 12.54 45 23651 36838 46625528
White blood cell count decreased 13.13 12.54 23 23673 112208 46550158
Hyperammonaemia 13.12 12.54 14 23682 4702 46657664
Ventricular fibrillation 13.04 12.54 22 23674 11474 46650892
Shock 13.01 12.54 32 23664 21813 46640553
Distributive shock 13.00 12.54 6 23690 515 46661851
Neglect of personal appearance 12.90 12.54 4 23692 113 46662253
Migraine 12.88 12.54 10 23686 70016 46592350
Abdominal discomfort 12.77 12.54 37 23659 151128 46511238
Red blood cell sedimentation rate abnormal 12.75 12.54 24 23672 13625 46648741
Presyncope 12.68 12.54 34 23662 24420 46637946
Myocardial ischaemia 12.65 12.54 23 23673 12726 46649640
Swollen tongue 12.59 12.54 38 23658 29194 46633172
Rash 12.59 12.54 118 23578 356394 46305972
Renal artery stenosis 12.56 12.54 9 23687 1779 46660587

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 280.61 13.54 254 15730 66948 29869546
Hypokalaemia 186.63 13.54 178 15806 50014 29886480
Acute kidney injury 154.04 13.54 403 15581 273439 29663055
Death 78.50 13.54 47 15937 357236 29579258
Drug interaction 62.06 13.54 240 15744 199328 29737166
Hypomagnesaemia 61.82 13.54 59 15925 16539 29919955
Lactic acidosis 56.13 13.54 76 15908 31137 29905357
Completed suicide 41.55 13.54 3 15981 99489 29837005
Bradycardia 39.13 13.54 99 15885 65427 29871067
Left atrial dilatation 35.62 13.54 18 15966 1793 29934701
Hypoosmolar state 33.52 13.54 8 15976 76 29936418
Drug abuse 32.81 13.54 3 15981 82069 29854425
Linear IgA disease 31.73 13.54 16 15968 1586 29934908
Hyperkalaemia 30.69 13.54 91 15893 65919 29870575
Confusional state 30.15 13.54 147 15837 134687 29801807
Oedema peripheral 30.14 13.54 124 15860 105708 29830786
Herbal interaction 30.11 13.54 10 15974 336 29936158
Angioedema 29.49 13.54 60 15924 34324 29902170
Dyspnoea exertional 29.41 13.54 61 15923 35369 29901125
Mucosal dryness 28.43 13.54 13 15971 1038 29935456
Consciousness fluctuating 26.03 13.54 12 15972 976 29935518
Neutrophilia 25.09 13.54 18 15966 3389 29933105
Myalgia 24.37 13.54 93 15891 76574 29859920
Hypotension 24.02 13.54 186 15798 200379 29736115
Renal artery arteriosclerosis 23.42 13.54 5 15979 27 29936467
Presyncope 22.85 13.54 35 15949 16021 29920473
Haematocrit increased 22.69 13.54 13 15971 1663 29934831
Tumour invasion 22.41 13.54 8 15976 335 29936159
Inappropriate antidiuretic hormone secretion 22.35 13.54 29 15955 11393 29925101
Gastrointestinal ischaemia 21.86 13.54 7 15977 209 29936285
Eosinophilia 21.83 13.54 41 15943 22119 29914375
Drug ineffective 21.57 13.54 101 15883 340286 29596208
Lip swelling 21.34 13.54 30 15954 12714 29923780
Flour sensitivity 20.72 13.54 5 15979 50 29936444
Renal artery restenosis 20.61 13.54 4 15980 12 29936482
Pancreatic neoplasm 20.24 13.54 10 15974 949 29935545
Ventricular flutter 20.05 13.54 5 15979 58 29936436
Syncope 19.99 13.54 94 15890 84809 29851685
Cholestasis 19.59 13.54 42 15942 24908 29911586
Electrolyte imbalance 19.15 13.54 27 15957 11473 29925021
Renal failure 19.12 13.54 126 15858 128840 29807654
Bundle branch block right 18.90 13.54 21 15963 7021 29929473
Product dose omission issue 18.72 13.54 13 15971 91618 29844876
Hypovolaemic shock 18.52 13.54 20 15964 6480 29930014
Thrombocytosis 18.45 13.54 15 15969 3398 29933096
Bundle branch block left 18.43 13.54 18 15966 5186 29931308
White blood cell count decreased 18.39 13.54 11 15973 83936 29852558
Haemoglobin increased 18.38 13.54 14 15970 2888 29933606
Atrioventricular block 18.33 13.54 21 15963 7261 29929233
Glycosylated haemoglobin decreased 18.33 13.54 7 15977 355 29936139
Polyuria 18.27 13.54 21 15963 7285 29929209
Atrial fibrillation 18.12 13.54 109 15875 108015 29828479
Nocturia 17.68 13.54 22 15962 8290 29928204
Hepatic ischaemia 17.56 13.54 7 15977 398 29936096
Tubulointerstitial nephritis 17.49 13.54 33 15951 17858 29918636
Wrong strength 17.37 13.54 5 15979 103 29936391
Febrile neutropenia 17.13 13.54 19 15965 106674 29829820
Electrocardiogram T wave abnormal 16.70 13.54 10 15974 1389 29935105
Pemphigoid 16.13 13.54 20 15964 7508 29928986
Gingival hypoplasia 16.00 13.54 3 15981 7 29936487
Ischaemic stroke 15.89 13.54 30 15954 16245 29920249
Metastases to peritoneum 15.71 13.54 10 15974 1547 29934947
External ear pain 15.46 13.54 3 15981 9 29936485
Arterial stenosis 15.26 13.54 9 15975 1216 29935278
Choroidal effusion 15.23 13.54 5 15979 162 29936332
Oral lichen planus 14.94 13.54 5 15979 172 29936322
Erectile dysfunction 14.82 13.54 31 15953 18071 29918423
Toxicity to various agents 14.77 13.54 47 15937 177136 29759358
Rash maculo-papular 14.73 13.54 38 15946 25380 29911114
Ephelides 14.30 13.54 4 15980 74 29936420
Metabolic acidosis 14.06 13.54 48 15936 37413 29899081
Infective exacerbation of chronic obstructive airways disease 13.81 13.54 9 15975 1449 29935045
Face oedema 13.78 13.54 23 15961 11311 29925183
Polydipsia 13.74 13.54 13 15971 3600 29932894
Mitral valve incompetence 13.68 13.54 25 15959 13209 29923285

Pharmacologic Action:

SourceCodeDescription
ATC C03BA11 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, EXCL. THIAZIDES
Sulfonamides, plain
ATC C09BX01 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors, other combinations
ATC C10BX13 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Lipid modifying agents in combination with other drugs
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175420 Thiazide-like Diuretic
CHEBI has role CHEBI:35498 diuretics
CHEBI has role CHEBI:35674 antihypertensive
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004232 Diuretics
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
MeSH PA D049993 Sodium Chloride Symporter Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Edema indication 267038008
Anuria contraindication 2472002 DOID:2983
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hyperparathyroidism contraindication 66999008 DOID:13543
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.53 acidic
pKa2 9.54 acidic
pKa3 5.52 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 12 member 3 Transporter INHIBITOR A2 7.54 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily KQT member 1 Ion channel WOMBAT-PK
Carbonic anhydrase 2 Enzyme Kd 6.70 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 8 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 6.67 CHEMBL
Carbonic anhydrase 13 Enzyme Kd 7 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.05 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 5.31 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 9.64 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.44 CHEMBL
Carbonic anhydrase 1 Enzyme Kd 5 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 6.56 CHEMBL
Carbonic anhydrase 6 Enzyme Kd 6.60 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.53 DRUG MATRIX
Carbonic anhydrase 13 Enzyme Ki 7.89 CHEMBL

External reference:

IDSource
4018746 VUID
N0000147050 NUI
D00345 KEGG_DRUG
180004-24-4 SECONDARY_CAS_RN
4018746 VANDF
C0021186 UMLSCUI
CHEBI:5893 CHEBI
BL1 PDB_CHEM_ID
CHEMBL406 ChEMBL_ID
DB00808 DRUGBANK_ID
D007190 MESH_DESCRIPTOR_UI
7203 IUPHAR_LIGAND_ID
3333 INN_ID
F089I0511L UNII
3702 PUBCHEM_CID
5764 RXNORM
2360 MMSL
4873 MMSL
d00260 MMSL
002313 NDDF
387419003 SNOMEDCT_US
725661001 SNOMEDCT_US
74213004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 0228-2571 TABLET, FILM COATED 2.50 mg ORAL ANDA 20 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 0228-2597 TABLET, FILM COATED 1.25 mg ORAL ANDA 20 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 21695-576 TABLET, FILM COATED 1.25 mg ORAL ANDA 20 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 42291-348 TABLET, FILM COATED 1.25 mg ORAL ANDA 19 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 42291-349 TABLET, FILM COATED 2.50 mg ORAL ANDA 19 sections
INDAPAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 43975-217 TABLET 1.25 mg ORAL ANDA 18 sections
INDAPAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 43975-304 TABLET 2.50 mg ORAL ANDA 18 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-024 TABLET, FILM COATED 1.25 mg ORAL ANDA 19 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-025 TABLET, FILM COATED 2.50 mg ORAL ANDA 19 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 62559-510 TABLET, FILM COATED 1.25 mg ORAL ANDA 19 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 62559-511 TABLET, FILM COATED 2.50 mg ORAL ANDA 19 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 63629-1953 TABLET, FILM COATED 1.25 mg ORAL ANDA 19 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 63629-1954 TABLET, FILM COATED 2.50 mg ORAL ANDA 19 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 68151-1294 TABLET, FILM COATED 1.25 mg ORAL ANDA 20 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 68788-7247 TABLET, FILM COATED 2.50 mg ORAL ANDA 20 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 71335-1541 TABLET, FILM COATED 1.25 mg ORAL ANDA 19 sections